Evaluating the Prognostic Value of a Pan-Cancer Circulating Tumor DNA Next-Generation Sequencing Panel in Advanced Cancer Patients
Longitudinal monitoring of ctDNA using a pan-cancer NGS panel provides meaningful prognostic information in patients with advanced cancers. Post-treatment ctDNA dynamics may better reflect disease progression than baseline ctDNA status alone, highlighting the need for further validation in larger cohorts, particularly in gastric, lung, head and neck, and esophageal cancers.
Authors
- Hoon Seok Kim (ORCID: https://orcid.org/0000-0001-8980-8177)
- Younmu Jung
- Myungshin Kim (ORCID: https://orcid.org/0000-0001-8632-0168)
- Seung Jung Han (ORCID: https://orcid.org/0000-0002-4038-6118)
- Seungok Lee (ORCID: https://orcid.org/0000-0003-4538-8427)
- Jaewoong Lee (ORCID: https://orcid.org/0000-0001-8318-050X)
- Jang Ho Cho
- Jae Ho Byun (ORCID: https://orcid.org/0000-0001-8198-5507)
Institutions
- Nexen (Canada) (CA)
- The Catholic University of Korea Incheon St. Mary's Hospital (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/ott.s537253
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Incheon St. Mary's Hospital, Catholic University of Korea